Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lonza Pharma & Biotech Launches Ibex Solutions | Contract Pharma

What are you searching for?

Sign in
Breaking News

Lonza Pharma & Biotech Launches Ibex Solutions

Represents an innovative new concept in biological manufacturing and development

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lonza has added a new technology to its portfolio—Ibex Solutions. The new biological development and manufacturing concept couples flexibility in facility-build-out with fully tailored business models and leverages Lonza’s expertise and service network in Visp, Switzerland. Construction began in June with a formal groundbreaking ceremony expected in the second half of 2017. Several hundred new positions are expected to be created.

Ibex biomanufacturing comprises a modular, technology-independent development and manufacturing complex capable of supporting activities across multiple technologies—mammalian, microbial, cellular or bio-conjugate—and from late discovery to manufacture. This flexibility gives customers complete freedom in facility design and implementation, and the ability to respond rapidly as their needs evolve.

Responsiveness is further enhanced by the integration of the Ibex biomanufacturing complex into the Visp site with its experienced workforce and established service networks.

Ibex Solutions include highly flexible models to match and adapt to each customer’s expectations and forecasts. The availability of a modular complex means time-to-market can be reduced by 12 months or more. These advantages contribute to a significant de-risking of major strategic investment decisions.

“Lonza has been creating innovative manufacturing and production solutions for 120 years, and we are continuing to pioneer clinical and commercial manufacturing in multiple technologies all over the world,” said Marc Funk, chief operating officer, Lonza’s Pharma & Biotech. “We have been working with our partners to understand what we can offer that will really change the game for them, and that’s why we have created Ibex.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics